Pustular psoriasis of pregnancy: Clinical and genetic characteristics in a series of eight patients and review of the literature

Dermatol Ther. 2022 Aug;35(8):e15593. doi: 10.1111/dth.15593. Epub 2022 May 30.

Abstract

Pustular psoriasis of pregnancy (PPP) can lead to life-threatening complications. The objective of this study is to report clinical and genetic spectrum, prognostic factors and management options. A retrospective study was designed including eight PPP patients. Clinical data were collected, and performed genetic and statistical analysis to identify factors associated with fetal complications, resistance to treatment and post-partum flare extension. A systematic review of the literature was also carried out. Eight Tunisian patients, with a mean age of 23 ± 3.3 years, were included. They presented 14 flares (F) during pregnancies and one flare after delivery. Additional GPP flares outside pregnancy periods were noted in 2/8 of patients. The mean duration of PPP flares was 16.66 ± 7.8 weeks. The first flare occurred at a gestational age of 26 ± 5 weeks. Only 2/8 studied patients presented a homozygous mutation c.80 T > C (p.L27P) in IL36RN gene. Used treatments were topical steroids (n = 12F), systemic steroids (n = 5F), ciclosporin (n = 1F), UVB (n = 1F) and acitretin (in post-partum n = 6F). Complications were oligoamnios (n = 2), intra-uterine growth retardation (n = 1), fetal death in utero (n = 1), prematurity (n = 3), low weight at birth (n = 2). A significant association was found between (i) occurrence of fetal complications and early gestational age at the onset (p = 0.036), (ii) resistance to topical steroids and body surface affected area (p = 0.008), (iii) presence of mutation c.80 T > C in PPP flares and low serum levels of calcium (p = 0.01). Our systematic review of the literature identified 39 patients with 41 flares of PPP. Only 7/39 patients presented a causative mutation in IL36RN and CARD14 genes. PPP is characterized by a phenotypic heterogeneity and can be associated to IL36RN mutations. Its early onset can be associated with fetal complications. Systemic steroids and cyclosporine remain the most used therapies.

Keywords: IL36RN mutations; generalized pustular psoriasis; prognostic factors; pustular psoriasis of pregnancy; treatment.

Publication types

  • Review

MeSH terms

  • Acitretin / therapeutic use
  • Adult
  • CARD Signaling Adaptor Proteins / genetics
  • Cyclosporine / therapeutic use
  • Female
  • Guanylate Cyclase / genetics
  • Guanylate Cyclase / therapeutic use
  • Humans
  • Infant
  • Infant, Newborn
  • Interleukins / genetics
  • Membrane Proteins / genetics
  • Membrane Proteins / therapeutic use
  • Pregnancy
  • Psoriasis* / diagnosis
  • Psoriasis* / drug therapy
  • Psoriasis* / genetics
  • Retrospective Studies
  • Skin Diseases, Vesiculobullous* / drug therapy
  • Steroids / therapeutic use
  • Young Adult

Substances

  • CARD Signaling Adaptor Proteins
  • IL36RN protein, human
  • Interleukins
  • Membrane Proteins
  • Steroids
  • Cyclosporine
  • CARD14 protein, human
  • Guanylate Cyclase
  • Acitretin